Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study

被引：0
|
作者：
Tan, X. [1 ]
Wu, Z. [1 ]
Wang, Y. [1 ]
Yao, K. [1 ]
机构：
[1] Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218P
引用
收藏
页码：S1560 / S1560
页数：1
相关论文
共 50 条
  • [1] Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma: A Real-World Study
    Wang, Yanjun
    Zhong, Kaihua
    Tan, Xingliang
    Zhou, Qianghua
    Jiang, Lijuan
    Yao, Kai
    Wu, Zhiming
    CANCER MEDICINE, 2025, 14 (04):
  • [2] Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study
    Quan, Penghe
    Hou, Haozhong
    Yang, Xiaojian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A realworld study
    Yang, Xiaojian
    Quan, Penghe
    Yu, Changjiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Racial differences in characteristics and outcomes of adjuvant nivolumab for muscle-invasive urothelial carcinoma (MIUC) in the real-world setting
    Barragan-Carrillo, Regina
    Chehrazi-Raffle, Alexander
    Feinberg, Bruce
    John, William S.
    Miller, Taavy A.
    Lucht, Sarah
    Pathak, Prathamesh
    Bland, Emily
    Gordon, Sarah
    Laney, JaLyna
    Klink, Andrew J.
    Ebrahimi, Hedyeh
    Singh, Nisha
    Alonso, Carmelo
    Patel, Miraj
    Rosenblatt, Lisa
    Yin, Xin
    CLINICAL CANCER RESEARCH, 2024, 30 (10)
  • [5] Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC)
    Dash, A.
    Pettus, J. A.
    Bochner, B. H.
    Dalbagni, G.
    Donat, S. M.
    Herr, H. W.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma
    Drakaki, Alexandra
    Pantuck, Allan
    Mhatre, Shivani K.
    Dhillon, Preet K.
    Davarpanah, Nicole
    Degaonkar, Viraj
    Surinach, Andy
    Chamie, Karim
    Grivas, Petros
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (01) : 76.e15 - 76.e22
  • [7] Tislelizumab combined with gemcitabine/cisplatin in muscle-invasive bladder cancer with selective bladder preservation for clinical complete response (cCR) patients: A real-world multicenter study
    Huang, B.
    Wang, Z.
    Wang, B.
    Yuan, D.
    Lin, H.
    Xu, A.
    Liu, P.
    Chen, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1217 - S1218
  • [8] Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
    Luo, Cheng
    Luo, Shuhang
    Wusimanjiang, Wumier
    Wang, Zongren
    Liu, Ping
    Wang, Bin
    Yuan, Dan
    Lin, Hao
    Xu, Abai
    Deng, Nan
    Wu, Kaihui
    Zhu, Xuejin
    Xu, Peng
    Chen, Junxing
    Huang, Bin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1759 - 1767
  • [9] Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study
    Quan, Penghe
    Zhang, Longlong
    Yang, Bo
    Hou, Haozhong
    Wu, Ningli
    Fan, Xiaozheng
    Yu, Changjiang
    Zhu, He
    Feng, Tianxi
    Zhang, Yifan
    Qu, Kejun
    Yang, Xiaojian
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03): : 1221 - 1231
  • [10] Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
    Chen, Wei
    Yoshida, Soichiro
    Miura, Noriyoshi
    Fukuda, Shohei
    Fukushima, Hiroshi
    Waseda, Yuma
    Tanaka, Hajime
    Fujii, Yasuhisa
    FRONTIERS IN ONCOLOGY, 2025, 14
12345